AzTrials
AzTrials

HealthyNCT06662695

Ginger and Plasma Cholesterol Efflux Capacity

A study testing Ginger-based supplement in people with Healthy, run by Shahid Beheshti University of Medical Sciences at 1 site in Iran.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

In light of the findings from experimental studies examining the effects of ginger-derived compounds on cholesterol efflux pathways, this study aims to investigate the impact of oral ginger supplementation on high-density lipoprotein (HDL) function. Read more about this study

Who is it for?
Ages 18 to 75 yearsHealthy volunteers can take part
Conditions the study is for
Healthy
What is being tested?
Ginger-based supplement
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
35 participants
Where
1 siteIran
Study dates
3 Nov 2024to 7 Apr 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • a body mass index less than 35 kg/m², Exclusion Criteria:

Who cannot join

  • Those with an allergy or sensitivity to ginger
  • Those who have used serum lipid-lowering or antiinflammatory drugs in the previous month regularly
  • Those who have regularly consumed ginger or ginger supplements (more than twice a week)

Trial locations and contacts

1 site in 1 country.

Iran1 site
  • Nutrition Clinic located in the Faculty of Nutrition Sciences, Shahid Beheshti University of Medical Sciences

    Tehran

Other trials in Iran

About this study

Official title: Effect of Oral Supplementation of Ginger on Plasma Cholesterol Efflux Capacity From THP-1 Macrophage

In light of the findings from experimental studies examining the effects of ginger-derived compounds on cholesterol efflux pathways, this study aims to investigate the impact of oral ginger supplementation on high-density lipoprotein (HDL) function. The crossover and double-blind study will be conducted in two four-week periods, with a minimum of three weeks between these two phases. In one of the two study periods, participants will receive a ginger supplement, while in the other period, they will receive a placebo in the form of capsules. At the outset and end of each study period, venous blood samples will be obtained from the subjects. Plasma and buffy coat (containing white blood cells) will be separated and stored at -80. Cholesterol efflux capacity (CEC) will be determined by adding participants' plasma samples to the culture medium of THP-1 cells. Additionally, the gene expression of ATP-binding cassette transporters (ABCA1) and ABCG1 will be determined in the tissue lining obtained from the blood samples of the participants.

Read the detailed description

The relationship between serum high-density lipoprotein cholesterol (HDL-C) and atherosclerosis was initially elucidated by the Framingham study. However, current evidence suggests that maintaining an optimal HDL-C level may not be sufficient to reduce the risk of cardiovascular disease (CVD). The majority of clinical trials have demonstrated that plasma HDL-C-raising drugs do not confer a reduction in the risk of developing CVD. Consequently, there has been a decline in interest in pursuing the elevation of HDL-C levels as a therapeutic objective. Mendelian randomization studies have called into question the causal relationship between plasma HDL-C levels and CVD. This may be due to factors related to HDL function and the reverse cholesterol transport pathway, including the effect of CEC. A number of studies involving large clinical populations have observed a robust inverse correlation between CEC and CVD after adjustment for plasma HDL-C levels. This suggests that CEC may serve as a more reliable biomarker for CVD than plasma HDL-C concentration. The efflux of cholesterol from macrophages may contribute to anti-inflammatory and anti-atherogenic effects, as well as reducing the accumulation of cholesterol esters in macrophages, which in turn leads to the production of foam cells. It is possible that ginger may affect this process. A limited number of in vitro studies have investigated the impact of ginger compounds on CEC, with all studies demonstrating a positive influence on the mediator of the reverse cholesterol transport pathway. These findings are in alignment with the results of an animal study in which hamsters fed a high-fat diet and ginger extract exhibited enhanced CEC. Moreover, it is conceivable that inflammatory processes may impede the efflux of cholesterol and the reverse cholesterol transport pathway. It can be reasonably deduced that the ginger, which exhibits antioxidant and anti-inflammatory properties, may prove beneficial in optimising this pathway. In light of the findings from experimental studies examining the effects of ginger-derived compounds on cholesterol efflux pathways, this study aims to investigate the impact of oral ginger supplementation on HDL function.

The crossover and double-blind study will be conducted in two four-week periods, with a washout period of at least three weeks between the two. The study population will be comprised of individuals who meet the following criteria: individuals between the ages of 18 and 75 years, with a body mass index less than 35 kg/m², who have not used serum lipid-lowering drugs in the previous month and have not regularly consumed ginger or ginger supplements (more than twice a week). In one of the two study periods, participants will ingest a ginger-based supplement in a dosage of 1500 mg, comprising three 500 mg capsules. In the other period, they will receive a placebo in the form of three capsules containing corn flour. A simple randomization method based on the RAS software is employed. To maintain the blind, the placebo and ginger capsules will be packed and coded in similar cans by an individual external to the study, and these capsules will remain sealed. At baseline and end of each study period, 6 cc of venous blood samples will be obtained from individuals after an overnight fast. The plasma and buffy coat (containing white blood cells) will be separated and stored at -80. Anthropometric measurements, including body weight, and blood pressure assessments will be conducted at baseline and end of each period. Additionally, a 24-hour food recall will be performed at both time points. The human monocyte cell line (THP-1) will be cultures in RPMI 1640 medium and subsequently differentiated into macrophage cells through the use of phorbol myristate acetate. Following differentiation, fluorescent cholesterol will be introduced to the culture medium in order to label the cells with this cholesterol. Subsequently, the plasma of the participants will be incorporated into the culture medium. Following the designated incubation period, the medium surrounding the cells will be removed and the cells will be lysed. The fluorescence of cholesterol in the medium and in the extract of THP-1 cells will be quantified using a fluorescence plate reader, allowing the calculation of CEC. The gene expression of ATP-binding cassette transporters A1 (ABCA1) and ATP-binding cassette transporters G1 (ABCG1) in the buffy coat obtained from blood samples of participants will be determined by quantitative polymerase chain reaction.

Conditions
Healthy
Being tested
Ginger-based supplement, Placebo
Keywords
Ginger, HDL, cholesterol efflux, ABCA1

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Ginger-based supplementDietary supplement

    Ginger-based supplement in a dosage of 1500 mg

  • PlaceboDietary supplement

    Capsules containing corn flour

Study groups in NCT06662695
Study groupRoleWhat they receive
GingerExperimentalGinger-based supplement
Receives: Dietary Supplement: Ginger-based supplement
PlaceboPlacebo comparatorCapsules containing corn flour
Receives: Dietary Supplement: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Ex-vivo plasma cholesterol efflux capacity

    The ex vivo plasma cholesterol efflux capacity of THP-1 cells labeled with fluorescent cholesterol

    Measured: up to 6 weeks

  2. Expression of ABCA1 and ABCG1

    The expression of genes encoding the ATP-binding cassette transporters ABCA1 and ABCG1 in peripheral white blood cells

    Measured: up to 6 weeks

Secondary outcomes (2)
  1. Plasma lipid profile

    The plasma concentrations of triglycerides, cholesterol, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol

    Measured: up to 6 weeks

  2. Plasma inflammatory biomarkers

    The plasma concentrations of c-reactive protein, interleukin 6

    Measured: up to 6 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Oct 2024
  2. Study start3 Nov 2024
  3. Primary completion1 Mar 2025
  4. Study completion7 Apr 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Crossover
Masking
Triple blind
Who is masked
Participant, Care provider, Outcomes assessor
Enrolment
35 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06662695
Sponsor's protocol ID
43008844
Status last verified
Apr 2025
First submitted
25 Oct 2024
Last updated
9 Apr 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A study testing Ginger-based supplement in people with Healthy, run by Shahid Beheshti University of Medical Sciences at 1 site in Iran.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 9 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Iran. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Ex-vivo plasma cholesterol efflux capacity (time frame: up to 6 weeks). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Apr 2025; AzTrials last refreshed its copy on 29 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in